| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC8536 | TAS-103 2HCl Featured | TAS-103 2Hcl(BMS-247615 2Hcl) is a dual inhibitor of topoisomerase-I (topo-I) and topoisomerase-II (topoII). |
|
| DC7898 | TAS-103(BMS247615) | TAS-103(BMS-247615) is a dual inhibitor of topoisomerase-I (topo-I) and topoisomerase-II (topoII). |
|
| DC8962 | Tegafur Featured | Tegafur (also known as Ftorafur) is a chemotherapeutic 5-FU prodrug used in the treatment of cancers; is a component of tegafur-uracil. |
|
| DC7725 | TH 287 Featured | TH 287 is a first-in-class MTH1 inhibitor (IC50 value 5.0 nM) that selectively and effectively kills U2OS and other cancer cell lines, with considerably less toxicity towards several primary or immortalized cells. |
|
| DC7689 | Evofosfamide(TH-302) Featured | TH-302 is selective hypoxia-activated prodrug targeting hypoxic regions of solid tumors with IC50 of 19 nM, demonstrates 270-fold enhanced cytotoxicity under hypoxia versus their potency under aerobic conditions, stable to cytochrome P450 metabolism. |
|
| DC7726 | TH 588 Featured | TH588 is a novel potent, selective and cell permeable inhibitor of the nudix hydrolase family MTH1 protein with an IC50 of ~5 nM. |
|
| DC6902 | Thiazovivin Featured | Thiazovivin is a rock inhibitor and enhances fibroblast reprogramming efficiency to generate stem cells |
|
| DC7653 | THZ1 free base Featured | THZ1 is a novel selective and potent covalent CDK7 inhibitor with IC50(binding affinity) of 3.2 nM; inhibits Jurkat cell's proliferation with IC50 of 50 nM. |
|
| DC10042 | THZ1 Hydrochloride Featured | THZ1 is a novel selective and potent covalent CDK7 inhibitor with IC50(binding affinity) of 3.2 nM; inhibits Jurkat cell's proliferation with IC50 of 50 nM. |
|
| DC10827 | THZ531 Featured | THZ531 is a covalent CDK12 and CDK13 covalent inhibitor. |
|
| DC8758 | Tipiracil hydrochloride Featured | Tipiralacil(TPI) is a thymidine phosphorylase inhibitor (TPI). Tipiracil is one of the active components in TAS-102, which is an anticancer drug candidate currently in clinical trials. |
|
| DC10611 | Trabectedin Featured | Trabectedin (Ecteinascidin-743 or ET-743) is a novel antitumour agent of marine origin with potent antitumour activity both in vitro and in vivo. |
|
| DC7522 | Triapine Featured | Triapine is a potent ribonucleotide reductase inhibitor with broad spectrum antitumor activity by inhibiting DNA synthesis. Phase 2. |
|
| DC7334 | UPF 1069 Featured | UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM; ~27-fold selective against PARP1. |
|
| DC3132 | VE-821 Featured | VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki and IC50 of 13 nM and 26 nM, respectively. |
|
| DC8899 | ABT888 (free base) Featured | Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM, respectively. |
|
| DC5150 | Veliparib (ABT-888 hydrochloride) Featured | Veliparib is a potent inhibitor of both PARP-1 and PARP-2 by [3H]NAD+ with Kis of 5.2 and 2.9 nmol/L, respectively. |
|
| DC7187 | Volasertib(BI6727) Featured | Volasertib(BI6727) is a highly potent PLK1 inhibitor with an IC50 of 0.87 nM; shows 6- and 65-fold greater selectivity against Plk2 and Plk3. |
|
| DC7530 | Voreloxin Featured | Voreloxin(SNS-595; AG 7352) is a small molecule and a naphthyridine analogue with antineoplastic activity; inhibitor of Topo II. |
|
| DC10750 | Voruciclib Featured | Voruciclib is a protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with potential antineoplastic activity. |
|
| DC3106 | VX-680 (MK-0457,Tozasertib) Featured | VX-680 (MK-0457, Tozasertib) is a pan-Aurora inhibitor of Aurora A, Aurora B and Aurora C with Kiapp of 0.6 nM, 18 nM and 4.6 nM, respectively. |
|
| DC8068 | WHI-P180(Janex 3) Featured | WHI-P180(Janex 3) is a potent inhibitor of IgE-mediated mast cell responses to allergens in vitro and in vivo. Also inhibits cyclin-dependent kinase 2 (CDK2; IC50 = 1µM) by blocking the ATP site |
|
| DC7533 | wiki4 Featured | WIKI4 is a novel Tankyrase inhibitor with IC50 of 15 nM for TNKS2, and leads to inhibition of Wnt/beta-catenin signaling. |
|
| DC1028 | Y-27632 2HCL Featured | Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM. |
|
| DC10375 | YU238259 Featured | YU238259 is a novel inhibitor of homology-dependent DNA repair(HDR), but does not inhibit non-homologous end-joining (NHEJ), in cell-based GFP reporter assays. |
|
| DC10167 | ZINC00881524 Featured | ZINC00881524 is a ROCK inhibitor. |
|
| DC1084 | ZM447439 (ZM-447439) Featured | ZM-447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. |
|
| DC11139 | ZYTP1 | ZYTP1 is a novel, oral PARP inhibitor that inhibits PARP1, PARP2, Tankyrase-1 and Tankyrase-2 with IC50 of 5.4, 0.7, 133.3 and 289.8 nM, respectively. |
|
| DC11254 | iCDK9 |
|
|
| DC11253 | Amt-87 |
|
